Vedolizumab's Real-World impact on Crohn's disease explored

NCT ID NCT05192863

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed observational study followed 72 adults with moderate to severe Crohn's disease who were starting vedolizumab treatment. The goal was to see if the drug could lead to complete remission—meaning no symptoms, normal inflammation markers, and healed bowel walls—after 12 months. Researchers used ultrasound to check bowel inflammation, alongside standard symptom scores and lab tests.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • A.O.U. Federico II

    Naples, 80131, Italy

  • ASST Fatebenefratelli Sacco

    Milan, 20157, Italy

  • Fondazione Ca' Granda Ospedale Maggiore Policlinico

    Milan, 20122, Italy

  • Hadassah Medical Center

    Jerusalem, 9112001, Israel

  • Ospedale ASST Rhodense

    Rho, Milano, 20017, Italy

  • Ospedale San Raffaele

    Milan, 20132, Italy

  • Rabin Medical Center

    Petah Tikva, 4941492, Israel

  • Sheba Medical Center

    Ramat Gan, 5262000, Israel

  • University of Calgary

    Calgary, Alberta, T2N 4N1, Canada

  • University of Saskatchewan

    Saskatoon, Saskatchewan, S7N 0W8, Canada